Literature DB >> 12587958

Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.

Z Yan1, B Rafferty, G W Caldwell, J A Masucci.   

Abstract

In this study we have evaluated the reliability of a fluorescence-based method used for rapid identification of irreversible CYP inhibitors (mechanism-based inhibitors). This was accomplished by comparing the time-dependence pattern of IC50 values from fluorometric kinetic measurements. For irreversible CYP inhibitors, IC50 values decreased as incubation proceeded. This was due to progressive inactivation of corresponding enzymes by reactive metabolites generated during the incubation. This change pattern was confirmed using a number of known irreversible CYP inhibitors, including furafylline, midazolam, erythromycin, clarithromycin, oleandomycin, 17alpha-ethynylestradiol and verapamil. The pattern was different in reversible inhibition, depending upon the compounds tested in the fluorometric kinetic assay. For some compounds, such as clotrimazole, IC50 values remained relatively stable, whereas other compounds, such as miconazole, terfenadine and ketoconazole showed a significant increase with incubation time. Monitoring tested compounds by LC-MS/MS during the incubation confirmed that increases of IC50 were probably caused by the loss of inhibitors, resulting from either metabolic degradation, or non-specific binding to microsomal proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12587958     DOI: 10.1007/BF03192339

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  21 in total

1.  Fluorometric screening for metabolism-based drug--drug interactions.

Authors:  C L Crespi; D M Stresser
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

Review 2.  Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.

Authors:  Z Yan; G W Caldwell
Journal:  Curr Top Med Chem       Date:  2001-11       Impact factor: 3.295

3.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.

Authors:  D Sutton; A M Butler; L Nadin; M Murray
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

4.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1997-12       Impact factor: 3.922

5.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

Authors:  C L Crespi; V P Miller; B W Penman
Journal:  Anal Biochem       Date:  1997-05-15       Impact factor: 3.365

6.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

Authors:  M Bourrié; V Meunier; Y Berger; G Fabre
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

7.  Inhibition of cytochromes P450 by antifungal imidazole derivatives.

Authors:  Wenjiang Zhang; Yamini Ramamoorthy; Tansel Kilicarslan; Helma Nolte; Rachel F Tyndale; Edward M Sellers
Journal:  Drug Metab Dispos       Date:  2002-03       Impact factor: 3.922

8.  Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers.

Authors:  T D Lindstrom; B R Hanssen; S A Wrighton
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.

Authors:  W Jacobsen; G Kirchner; K Hallensleben; L Mancinelli; M Deters; I Hackbarth; L Z Benet; K F Sewing; U Christians
Journal:  Drug Metab Dispos       Date:  1999-02       Impact factor: 3.922

10.  In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  1994-12       Impact factor: 3.126

View more
  4 in total

1.  Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus.

Authors:  Brian H Harvey; Frasia Oosthuizen; Linda Brand; Gregers Wegener; Dan J Stein
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

2.  Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models.

Authors:  Le Yang; Chenyang Yan; Feng Zhang; Bo Jiang; Shouhong Gao; Youtian Liang; Lifeng Huang; Wansheng Chen
Journal:  Exp Anim       Date:  2017-11-13

3.  Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.

Authors:  Carlos A Fuzo; Ronaldo B Martins; Thais F C Fraga-Silva; Martin K Amstalden; Thais Canassa De Leo; Juliano P Souza; Thais M Lima; Lucia H Faccioli; Débora Noma Okamoto; Maria Aparecida Juliano; Suzelei C França; Luiz Juliano; Vania L D Bonato; Eurico Arruda; Marcelo Dias-Baruffi
Journal:  Drug Dev Res       Date:  2022-08-21       Impact factor: 5.004

4.  Acetylcholinesterase inhibitory activity of pigment echinochrome A from sea urchin Scaphechinus mirabilis.

Authors:  Sung Ryul Lee; Julius Ryan D Pronto; Bolor-Erdene Sarankhuu; Kyung Soo Ko; Byoung Doo Rhee; Nari Kim; Natalia P Mishchenko; Sergey A Fedoreyev; Valentin A Stonik; Jin Han
Journal:  Mar Drugs       Date:  2014-06-10       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.